0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Trends in Prostate Cancer Incidence and Mortality Rates

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          How are prostate cancer incidence and mortality rates changing in California, and do trends vary by stage, age, race and ethnicity, or region?

          Findings

          In this cohort study of males in California between 2004 and 2021, there were 387 636 cases of prostate cancer; the incidence rate of distant prostate cancer increased 6.7% per year, on average, between 2011 and 2021. On average, prostate cancer mortality rates declined 2.6% per year between 2004 and 2012 but plateaued between 2012 and 2021; trends in incidence and mortality were similar across age, race or ethnicity, and region.

          Meaning

          These findings suggest that in the 2010s, distant stage prostate cancer increased and mortality rates plateaued throughout California.

          Abstract

          This cohort study examines the trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region of California.

          Abstract

          Importance

          Incidence of distant stage prostate cancer is increasing in the United States. Research is needed to understand trends by social and geographic factors.

          Objective

          To examine trends in prostate cancer incidence and mortality rates in California by stage, age, race and ethnicity, and region.

          Design, Setting, and Participants

          This cohort study used mortality data from the California Cancer Registry and California Department of Public Health's Center for Health Statistics, and incidence data from the National Cancer Institute Surveillance, Epidemiology, and End Results program and the US Census. The dataset for these analyses was released in April 2024. Participants included males residing in California between 2004 and 2021. Analyses were conducted from April to October 2024.

          Exposures

          Stage at diagnosis, age, race and ethnicity, and region of California.

          Main Outcomes and Measures

          The delay-adjusted incidence rates and mortality rates were calculated and age-adjusted to the 2000 US standard population. Annual percentage changes (APC) were calculated using NCI’s Joinpoint Regression Program.

          Results

          Between 2004 and 2021, there were 387 636 prostate cancer cases (27 938 distant stage) and 58 754 prostate cancer deaths in California. In this study, 203 038 cases (52.4%) occurred among males aged 55 to 69 years, and 153 884 (39.7%) occurred among males 70 years or older. The distribution of race and ethnicity among cases was: 1031 American Indian or Alaska Native (0.3%); 31 366 Asian American, Native Hawaiian, and Pacific Islander (8.1%); 66 695 Hispanic or Latino (17.2%); 36 808 non-Hispanic Black (9.5%); 238 229 non-Hispanic White (61.5%); and 13 507 unknown or other races (3.5%). On average, the incidence of distant prostate cancer increased 6.7% (95% CI, 6.2% to 7.3%) per year between 2011 and 2021. By race and ethnicity, the APC ranged from 6.5% (95% CI, 4.2% to 13.4%) among Asian American, Native Hawaiian, and Pacific Islander males between 2011 and 2021 to 8.0% (95% CI, 6.9% to 9.5%) among Hispanic males between 2014 and 2021. In 9 of the 10 California regions, the incidence of distant prostate cancer increased by approximately 6% or more per year. Prostate cancer mortality rates declined 2.6% per year between 2004 and 2012 but plateaued between 2012 to 2021 (APC, 0.1%; 95% CI, −0.6% to 1.6%). The plateau in mortality occurred across ages, races and ethnicities, and regions.

          Conclusions and relevance

          In this cohort study among California residents, the incidence of distant stage prostate cancer increased throughout the state between 2011 and 2021. Mortality rates plateaued between 2012 and 2021, ending previous decades of decline. Implementation of more effective prostate cancer screening strategies are critically needed.

          Related collections

          Most cited references11

          • Record: found
          • Abstract: found
          • Article: not found
          Is Open Access

          Cancer statistics, 2023

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected by the National Center for Health Statistics. In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women. For example, lung cancer in women decreased at one half the pace of men (1.1% vs. 2.6% annually) from 2015 through 2019, and breast and uterine corpus cancers continued to increase, as did liver cancer and melanoma, both of which stabilized in men aged 50 years and older and declined in younger men. However, a 65% drop in cervical cancer incidence during 2012 through 2019 among women in their early 20s, the first cohort to receive the human papillomavirus vaccine, foreshadows steep reductions in the burden of human papillomavirus-associated cancers, the majority of which occur in women. Despite the pandemic, and in contrast with other leading causes of death, the cancer death rate continued to decline from 2019 to 2020 (by 1.5%), contributing to a 33% overall reduction since 1991 and an estimated 3.8 million deaths averted. This progress increasingly reflects advances in treatment, which are particularly evident in the rapid declines in mortality (approximately 2% annually during 2016 through 2020) for leukemia, melanoma, and kidney cancer, despite stable/increasing incidence, and accelerated declines for lung cancer. In summary, although cancer mortality rates continue to decline, future progress may be attenuated by rising incidence for breast, prostate, and uterine corpus cancers, which also happen to have the largest racial disparities in mortality.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Cancer statistics for African American/Black People 2022

            African American/Black individuals have a disproportionate cancer burden, including the highest mortality and the lowest survival of any racial/ethnic group for most cancers. Every 3 years, the American Cancer Society estimates the number of new cancer cases and deaths for Black people in the United States and compiles the most recent data on cancer incidence (herein through 2018), mortality (through 2019), survival, screening, and risk factors using population-based data from the National Cancer Institute and the Centers for Disease Control and Prevention. In 2022, there will be approximately 224,080 new cancer cases and 73,680 cancer deaths among Black people in the United States. During the most recent 5-year period, Black men had a 6% higher incidence rate but 19% higher mortality than White men overall, including an approximately 2-fold higher risk of death from myeloma, stomach cancer, and prostate cancer. The overall cancer mortality disparity is narrowing between Black and White men because of a steeper drop in Black men for lung and prostate cancers. However, the decline in prostate cancer mortality in Black men slowed from 5% annually during 2010 through 2014 to 1.3% during 2015 through 2019, likely reflecting the 5% annual increase in advanced-stage diagnoses since 2012. Black women have an 8% lower incidence rate than White women but a 12% higher mortality; further, mortality rates are 2-fold higher for endometrial cancer and 41% higher for breast cancer despite similar or lower incidence rates. The wide breast cancer disparity reflects both later stage diagnosis (57% localized stage vs 67% in White women) and lower 5-year survival overall (82% vs 92%, respectively) and for every stage of disease (eg, 20% vs 30%, respectively, for distant stage). Breast cancer surpassed lung cancer as the leading cause of cancer death among Black women in 2019. Targeted interventions are needed to reduce stark cancer inequalities in the Black community.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system

                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                27 January 2025
                January 2025
                27 January 2025
                : 8
                : 1
                : e2456825
                Affiliations
                [1 ]Department of Epidemiology and Biostatistics, University of California, San Francisco
                [2 ]Department of Urology, University of California, San Francisco
                [3 ]Greater Bay Area Cancer Registry, University of California, San Francisco
                Author notes
                Article Information
                Accepted for Publication: November 21, 2024.
                Published: January 27, 2025. doi:10.1001/jamanetworkopen.2024.56825
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2025 Van Blarigan EL et al. JAMA Network Open.
                Corresponding Author: Erin L. Van Blarigan, ScD, UCSF Box 0560, 550 16th St, 2nd Floor, San Francisco, CA 94158 ( erin.vanblarigan@ 123456ucsf.edu ).
                Author Contributions: Dr Van Blarigan and Ms McKinley had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Van Blarigan, Cooperberg, Gomez.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: Van Blarigan, McKinley.
                Critical review of the manuscript for important intellectual content: All authors.
                Statistical analysis: Van Blarigan, McKinley.
                Obtained funding: Gomez.
                Administrative, technical, or material support: McKinley, Gomez.
                Supervision: Washington, Gomez.
                Conflict of Interest Disclosures: Dr Van Blarigan reported receiving grants from the National Cancer Institute during the conduct of the study. Dr Cooperberg reported receiving personal fees from Astellas, Astra Zeneca, Pfizer, Bayer, Veracyte, ExosomeDx, Lynx Dx, Merck, and Verana Health outside the submitted work. Dr Kenfield reported receiving personal fees from Fellow Health for consulting outside the submitted work. Dr Gomez reported receiving grants from the National Cancer Institute during the conduct of the study. No other disclosures were reported.
                Funding/Support: The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 1NU58DP007156; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN261201800032I awarded to the University of California, San Francisco, contract HHSN261201800015I awarded to the University of Southern California, and contract HHSN261201800009I awarded to the Public Health Institute, Cancer Registry of Greater California.
                Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their contractors and subcontractors.
                Data Sharing Statement: See Supplement 2.
                Article
                zoi241591
                10.1001/jamanetworkopen.2024.56825
                11774093
                39869333
                95d7448c-ab06-4c50-b2c8-ef66718a5848
                Copyright 2025 Van Blarigan EL et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 16 July 2024
                : 21 November 2024
                Categories
                Research
                Original Investigation
                Online Only
                Urology

                Comments

                Comment on this article